News
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...
Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...
5d
GlobalData on MSNDupixent sales spur Sanofi growth, but profits fall short
Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...
Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.
In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on TV ads for prescription drugs reached a low not seen since this time last ...
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results